We are international
Donate
TEXT SIZE   


Myeloma Minute
November 19, 2015
11.19.15
November 19, 2015
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF
   

 
This week's question: Which is preferable: a second autologous stem cell transplant or novel therapies?


Multiple Myeloma Bone Study

New ARROW Clinical Trials: Learn How To Participate

New Selinexor STORM Clinical Trials: Learn How To Participate

New Ixazomib Clinical Trials: Learn How To Participate

Join the conversation about myeloma on the Smart Patients Message Board

Upcoming Events

Thursday, November 19, 2015
Living Well with Myeloma

"Myeloma 101: Updates on Treatment & Pain Management"

Saturday, November 21, 2015
Regional Community Workshop

Chicago, Illinois

Saturday, November 28, 2015
Doris Morgan's 75th Birthday Gala

Atlanta, Georgia

 

Friday, December 4, 2015
IMF Satellite Symposium

Orlando, Florida/Live Stream

 

 

    

x

Best Myeloma Research from American Society of Hematology (ASH) 2015 Annual Meeting

In his blog this week, IMF Chairman Dr. Brian Durie offers a sneak peek of the most interesting research to be presented at the 57th Annual Meeting of the American Society of Hematology, Dec. 5-8, in Orlando, FL. “The selection of the ‘top’ abstracts at ASH is always somewhat personal,” he notes, “but IMF Medical Editor Debbie Birns and I have picked a combination of research and clinically important topics as the ‘best’ this year.” Their task was made daunting by the volume of abstracts dealing with myeloma this year—784! To read Dr. Durie’s blog, click HERE.

x

European Commission Approves Kyprolis (carzfilzomib) for Use in Combination with Other Treatments for the Care of Patients with Relapsed Multiple Myeloma



 

The IMF is pleased to announce that today the European Commission (EC) approved the use of Kyprolis® (carzfilzomib) for use in combination with lenalidodmide and dexamethasone to treat patients with multiple myeloma who have received at least one prior treatment.

According to Professor Meletios A. Dimopouls, MD, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, “In clinical studies, approximately one out of three patients achieved a complete response or better on Krypolis® in combination with lenalidomide and dexamethasone arm, which is three times more frequent than in the lenalidomide and dexamethasone arm.” He noted that in patients with relapsed myeloma, “this regimen provided patients with more than two years without disease progression.”

Krypolis® (“kye-PRO-lis”) is the second drug to have been developed in a new class of drugs called proteasome inhibitors and approved by the US Food and Drug Administration (FDA). Proteasome inhibitors work by blocking the activity of enzyme complexes called proteasomes. Both normal cells and cancer cells contain proteasomes, which break down damaged and unwanted proteins into smaller components. Proteasomes also carry out the regulated breakdown of undamaged proteins in the cell, a process that is critical to cellular functions. These smaller components are then used to create new proteins required by the cell. Proteasomes can be thought of as crucial to the cell’s “recycling” of proteins.

Approval from the European Commission allows for centralized marketing authorization of the drug with unified labeling in the 28-member countries of the European Union. The members of the European Economic Area (Norway, Iceland, and Lichenstein) will make their decisions based on the decisions of the EC.

To learn more about AMGEN’s announcement of this approval, click HERE.

x

Fall 2015 Issue of Myeloma Today Traces 25 Years of the IMF



 

The IMF’s quarterly publication, Myeloma Today, is now available online and commemorates the 25th anniversary of the International Myeloma Foundation! In this special issue, IMF President and Co-Founder Susie Novis Durie recalls the IMF’s humble beginnings in a coffee shop in London. Readers can catch up on the latest developments in the Black Swan Research Initiative, which will launch “cure” trials in both the US and Europe. And the connection between African Americans and multiple myeloma is explored. Finally, we share all the details and images from our recent 9th Annual Comedy Celebration that raised $600,000 to fight myeloma. To read more, click HERE.

x

Connect to a Livestream from ASH 2015: "Global Advances in Myeloma: Providing Best Options for Myeloma Treatment in 2015"


 

The 57th American Society of Hematology (ASH) annual meeting, a gathering over 20,000 health care professionals from around the world, begins on December 5th in Orlando, Florida. Preceding its kick-off, the Friday Satellite Symposium will take place from 12:30 PM ET / 9:30 AM PST to 3:00 PM ET / 12:30 PM PST on December 4th, and the IMF will provide a live webcast from the event. Tune in to hear international experts debate and discuss how recent updates and practice changes affect therapeutic decisions faced by clinicians treating myeloma in the frontline and relapsed settings in 2015 and beyond. For more information and to register, click HERE.

 

Watch the Livestream from ASH 2015: The International Myeloma Working Group (IMWG) Conference Series


 

 Don’t miss the IMWG Conference series panel on “Making Sense of Treatment,” happening Monday, December 7th, at 8 PM ET / 5 PM PST. Drs. Brian G.M. Durie (IMF Chairman), Joseph Mikhael, Antonio Palumbo, and Paul Richardson discuss the latest news and trends in the treatment of multiple myeloma.To register, please click HERE.

 

 


Join Our Mailing List

 
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF InfoLine: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe
www.myeloma.org

.

 


 related articles